VWWMG
KYTX icon

Vermillion & White Wealth Management Group’s Kyverna Therapeutics KYTX Stock Holding History

Vermillion & White Wealth Management Group’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,100
Closed -$10.3K – 554
2025
Q4 		$10.3K Buy
+1,100
New +$8.17K 0.01% 315

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Vermillion & White Wealth Management Group's KYTX Position: Q1 2026 in Review

Vermillion & White Wealth Management Group sold out of Kyverna Therapeutics (KYTX) in Q1 2026, closing a stake of 1,100 shares — an estimated $10.3K sold.

Vermillion & White Wealth Management Group first reported a position in KYTX in Q4 2025 and held it in 1 quarter. The position peaked at $10.3K in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Vermillion & White Wealth Management Group reported no remaining Kyverna Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Vermillion & White Wealth Management Group sold 1,100 Kyverna Therapeutics shares in Q1 2026, an estimated $10.3K.
  • Vermillion & White Wealth Management Group first reported a position in Kyverna Therapeutics in Q4 2025 and held it in 1 quarter.
  • Vermillion & White Wealth Management Group's Kyverna Therapeutics position peaked at $10.3K in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Vermillion & White Wealth Management Group's 13F filing for Q1 2026, filed 14 May 2026.